Thus, dalantercept is considered a promising inhibitor for treating RCC, in which escape from VEGF-mediated tumor angiogenesis is critical (Philips & Atkins, 2014; Wang et al., 2016). The gene discussed is VEGFA; the disease is neoplasm.